Failed renoprotection by alternatively activated bone marrow macrophages is due to a proliferation-dependent phenotype switch in vivo
- PMID:24048378
- DOI: 10.1038/ki.2013.341
Failed renoprotection by alternatively activated bone marrow macrophages is due to a proliferation-dependent phenotype switch in vivo
Abstract
Alternatively activated macrophages (M2) regulate immune responses and ex vivo polarized splenic M2 are able to ameliorate renal injury including models of renal disease, such as adriamycin nephropathy. Whether M2 derived from other organs have similar protective efficacy is unknown. Here, we report adoptively transferred bone marrow M2 macrophages did not improve renal function or reduce renal injury in adriamycin nephropathy, whereas splenic M2 macrophages were protective. Bone marrow and splenic M2 macrophages showed similar regulatory phenotypes and suppressive functions in vitro. Within the inflamed kidney, suppressive phenotypes in bone marrow but not in splenic M2 macrophages, were dramatically reduced. Loss of the suppressive phenotype in bone marrow M2 was related to strong proliferation of bone marrow M2. Bone marrow M2 proliferation in vivo correlated with M-CSF expression by tubular cells in the inflamed kidney. Inhibition of M-CSF in vitro limited bone marrow M2 proliferation and prevented switch of phenotype. Proliferating cells derived from transfused bone marrow M2 were inflammatory rather than regulatory in their phenotype and function. Thus bone marrow in contrast to splenic M2 macrophages do not protect against renal structural and functional injury in murine adriamycin nephropathy. The failed renoprotection of bone marrow M2 is due to the switch of transfused M2 macrophages from a regulatory to an inflammatory phenotype.
Comment in
- Alternatively activated macrophages as therapeutic agents for kidney disease: in vivo stability is a key factor.Alagesan S, Griffin MD.Alagesan S, et al.Kidney Int. 2014 Apr;85(4):730-3. doi: 10.1038/ki.2013.405.Kidney Int. 2014.PMID:24682117
Similar articles
- Alternatively activated macrophages as therapeutic agents for kidney disease: in vivo stability is a key factor.Alagesan S, Griffin MD.Alagesan S, et al.Kidney Int. 2014 Apr;85(4):730-3. doi: 10.1038/ki.2013.405.Kidney Int. 2014.PMID:24682117
- Transfused macrophages ameliorate pancreatic and renal injury in murine diabetes mellitus.Zheng D, Wang Y, Cao Q, Lee VW, Zheng G, Sun Y, Tan TK, Wang Y, Alexander SI, Harris DC.Zheng D, et al.Nephron Exp Nephrol. 2011;118(4):e87-99. doi: 10.1159/000321034. Epub 2011 Feb 11.Nephron Exp Nephrol. 2011.PMID:21311199
- Ex vivo programmed macrophages ameliorate experimental chronic inflammatory renal disease.Wang Y, Wang YP, Zheng G, Lee VW, Ouyang L, Chang DH, Mahajan D, Coombs J, Wang YM, Alexander SI, Harris DC.Wang Y, et al.Kidney Int. 2007 Aug;72(3):290-9. doi: 10.1038/sj.ki.5002275. Epub 2007 Apr 18.Kidney Int. 2007.PMID:17440493
- Macrophages in renal disease.Wang Y, Harris DC.Wang Y, et al.J Am Soc Nephrol. 2011 Jan;22(1):21-7. doi: 10.1681/ASN.2010030269.J Am Soc Nephrol. 2011.PMID:21209251Review.
- Macrophage polarization and function with emphasis on the evolving roles of coordinated regulation of cellular signaling pathways.Zhou D, Huang C, Lin Z, Zhan S, Kong L, Fang C, Li J.Zhou D, et al.Cell Signal. 2014 Feb;26(2):192-7. doi: 10.1016/j.cellsig.2013.11.004. Epub 2013 Nov 9.Cell Signal. 2014.PMID:24219909Review.
Cited by
- Reparative macrophage transplantation for myocardial repair: a refinement of bone marrow mononuclear cell-based therapy.Podaru MN, Fields L, Kainuma S, Ichihara Y, Hussain M, Ito T, Kobayashi K, Mathur A, D'Acquisto F, Lewis-McDougall F, Suzuki K.Podaru MN, et al.Basic Res Cardiol. 2019 Aug 1;114(5):34. doi: 10.1007/s00395-019-0742-1.Basic Res Cardiol. 2019.PMID:31372765Free PMC article.
- Reprogramming Metabolism of Macrophages as a Target for Kidney Dysfunction Treatment in Autoimmune Diseases.Tian F, Chen H, Zhang J, He W.Tian F, et al.Int J Mol Sci. 2022 Jul 21;23(14):8024. doi: 10.3390/ijms23148024.Int J Mol Sci. 2022.PMID:35887371Free PMC article.Review.
- Targeting Macrophages: Therapeutic Approaches in Diabetic Kidney Disease.Lin DW, Yang TM, Ho C, Shih YH, Lin CL, Hsu YC.Lin DW, et al.Int J Mol Sci. 2024 Apr 15;25(8):4350. doi: 10.3390/ijms25084350.Int J Mol Sci. 2024.PMID:38673935Free PMC article.Review.
- Macrophage heterogeneity, phenotypes, and roles in renal fibrosis.Cao Q, Wang Y, Harris DC.Cao Q, et al.Kidney Int Suppl (2011). 2014 Nov;4(1):16-19. doi: 10.1038/kisup.2014.4.Kidney Int Suppl (2011). 2014.PMID:26312145Free PMC article.Review.
- Macrophages derived from pluripotent stem cells: prospective applications and research gaps.Lyadova I, Vasiliev A.Lyadova I, et al.Cell Biosci. 2022 Jun 20;12(1):96. doi: 10.1186/s13578-022-00824-4.Cell Biosci. 2022.PMID:35725499Free PMC article.Review.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials